Literature DB >> 20368223

What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management.

Clifford J Bailey1, Lawrence Blonde, Stefano Del Prato, Lawrence A Leiter, Richard Nesto.   

Abstract

The Global Partnership for Effective Diabetes Management was established in 2004 to provide practical guidance to improving glycaemic control for people with type 2 diabetes. Those recommendations have been updated to take account of recent trials assessing the effects of intensive glucose control. We continue to emphasis the importance of early and sustained glycaemic control, aiming for HbA( 1c) 6.5-7% wherever safe and appropriate. Individualisation of targets and the management process is strongly encouraged to accommodate patient circumstances and to avoid hypoglycaemia. Prompt introduction of combinations of agents is suggested when monotherapy is inadequate.Treatments will preferably address the underlying pathophysiology of type 2 diabetes and integrate within a wider programme of care which also aims to reduce modifiable cardiovascular risk factors and better equip patients in the self-management of their condition.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20368223     DOI: 10.1177/1479164109341691

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  6 in total

1.  New therapeutic algorithm of Type 2 diabetes: lights and shadows.

Authors:  A Consoli
Journal:  J Endocrinol Invest       Date:  2011-02-04       Impact factor: 4.256

Review 2.  Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management.

Authors:  S Del Prato; J LaSalle; S Matthaei; C J Bailey
Journal:  Int J Clin Pract       Date:  2010-02       Impact factor: 2.503

Review 3.  Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.

Authors:  Angela Dardano; Cristina Bianchi; Stefano Del Prato; Roberto Miccoli
Journal:  Vasc Health Risk Manag       Date:  2014-08-05

4.  Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.

Authors:  Helene Hausner; Julie Derving Karsbøl; Anders G Holst; Jacob B Jacobsen; Frank-Dietrich Wagner; Georg Golor; Thomas W Anderson
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

5.  Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.

Authors:  Monika Kellerer; Margit Staum Kaltoft; Jack Lawson; Lasse Lykke Nielsen; Krzysztof Strojek; Ömür Tabak; Stephan Jacob
Journal:  Diabetes Obes Metab       Date:  2022-06-29       Impact factor: 6.408

6.  Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.

Authors:  J Hans DeVries; Cyrus Desouza; Srikanth Bellary; Jeffrey Unger; Oluf K H Hansen; Jeppe Zacho; Vincent Woo
Journal:  Diabetes Obes Metab       Date:  2018-07-09       Impact factor: 6.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.